Sign in
ALEC Stock Price, Chart, Stats & News
Alector, Inc.
Save
194.29M
Market cap
–
Current P/E
8.47x
Forward P/E
ALEC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 89.27% |
Operating margin | -692.83% |
Pretax margin | -678.36% |
Net margin | -679.16% |
Effective tax rate | -0.12% |
ROA | -48.74% |
ROE | -224.96% |
D/E | 1.18x |
Interest coverage ratio | – |
ALEC valuation
P/E | – |
P/S | 10.49x |
P/B | 6.72x |
P/CF | -1.12x |
P/FCF | -1.20x |
P/OCF | -1.12x |
PEG | 0.05x |
EV multiple | -1.83x |
About
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Similar securities
Based on sector and market capitalization
Report issue